Literature DB >> 20223049

Disease burden of post-infectious irritable bowel syndrome in The Netherlands.

J A Haagsma1, P D Siersema, N J De Wit, A H Havelaar.   

Abstract

Post-infectious irritable bowel syndrome (PI-IBS) has been established as a sequel of infectious intestinal disease (IID). The aim of this study was to estimate the burden of PI-IBS caused by the pathogens Campylobacter, Salmonella and Shigella, and to compare this with other outcomes associated with these pathogens. The attributable risk of PI-IBS due to bacterial pathogens was calculated and linked to national data on gastroenteritis incidence and measures for severity and duration of illness in order to estimate the burden of PI-IBS. One year post-infection, IBS developed in 9% of patients with bacterial IID. The burden of PI-IBS adds over 2300 disability adjusted life years to the total annual disease burden for the selected pathogens. PI-IBS is a frequent sequel of IID, resulting in a considerable disease burden compared to other outcomes. If this relationship is not considered, this will result in an underestimation of the disease burden of IID.

Entities:  

Mesh:

Year:  2010        PMID: 20223049     DOI: 10.1017/S0950268810000531

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  33 in total

Review 1.  Salmonella Serogroup C: Current Status of Vaccines and Why They Are Needed.

Authors:  Fabien J Fuche; Ousmane Sow; Raphael Simon; Sharon M Tennant
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

Review 2.  Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas.

Authors:  Margaret Kosek; Pablo Peñataro Yori; Maribel Paredes Olortegui
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

3.  Prevalence of Campylobacter jejuni and Campylobacter coli in captive wildlife species of India.

Authors:  A A Prince Milton; R K Agarwal; G B Priya; M Saminathan; M Aravind; A Reddy; C K Athira; T P Ramees; K Dhama; A K Sharma; A Kumar
Journal:  Iran J Vet Res       Date:  2017       Impact factor: 1.376

Review 4.  Advances in the treatment of travelers' diarrhea.

Authors:  Mercedes Paredes-Paredes; Jose Flores-Figueroa; Herbert L Dupont
Journal:  Curr Gastroenterol Rep       Date:  2011-10

5.  Antimicrobial resistance and antimicrobial use associated with laboratory-confirmed cases of Campylobacter infection in two health units in Ontario.

Authors:  Anne E Deckert; Richard J Reid-Smith; Susan E Tamblyn; Larry Morrell; Patrick Seliske; Frances B Jamieson; Rebecca Irwin; Catherine E Dewey; Patrick Boerlin; Scott A McEwen
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.

Authors:  Adam Deising; Ramiro L Gutierrez; Chad K Porter; Mark S Riddle
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-03

7.  An experience with the Patient-Reported Outcomes Measurement Information System: pros and cons and unanswered questions.

Authors:  Terry A Badger; Margaret Heitkemper; Kathryn A Lee; Deborah Watkins Bruner
Journal:  Nurs Outlook       Date:  2014-07-10       Impact factor: 3.250

8.  An assessment of the human health impact of seven leading foodborne pathogens in the United States using disability adjusted life years.

Authors:  E Scallan; R M Hoekstra; B E Mahon; T F Jones; P M Griffin
Journal:  Epidemiol Infect       Date:  2015-01-30       Impact factor: 4.434

9.  Economics of zoonoses surveillance in a 'One Health' context: an assessment of Campylobacter surveillance in Switzerland.

Authors:  S Babo Martins; J Rushton; K D C Stärk
Journal:  Epidemiol Infect       Date:  2017-01-23       Impact factor: 4.434

10.  Risk factors for campylobacteriosis of chicken, ruminant, and environmental origin: a combined case-control and source attribution analysis.

Authors:  Lapo Mughini Gras; Joost H Smid; Jaap A Wagenaar; Albert G de Boer; Arie H Havelaar; Ingrid H M Friesema; Nigel P French; Luca Busani; Wilfrid van Pelt
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.